Navigation Links
Positive Results for Ophthotech's Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
Date:5/4/2009

59% of patients showed 3-line gain (significant visual gain) and 100% neovascular regression

FORT LAUDERDALE, Fla., May 4 /PRNewswire/ -- Ophthotech Corp. today announced positive results of a phase 1 clinical study evaluating E10030, its novel anti-platelet derived growth factor (anti-PDGF) in conjunction with an anti-vascular endothelial growth factor (anti-VEGF), to treat wet age-related macular degeneration (wet AMD). Anti-PDGF therapy resulted in enhanced visual outcome and was associated with significant neovascular regression. The results were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting in Fort Lauderdale.

59% percent of patients treated with anti-PDGF and anti-VEGF gained significant vision (3-line gain) at week 12 after therapy. 100% of treated patients demonstrated neovascular regression. E10030 was well tolerated with no evidence of drug-related adverse events. Current standard of care treatment utilizing monotherapy anti-VEGF results in 3-line visual gain in approximately one third of patients and without significant neovascular regression.

"Marked neovascular regression, a first in any study, with an outstanding level of visual gain, is very promising for our patients. My clinical experience with current monotherapy anti-VEGF regimen in wet AMD is consistent with published studies, which show that on average neovascular regression does not occur," said Dr. Lawrence J. Singerman, Clinical Professor at Case Western Reserve University and a principal investigator in over 50 macular clinical trials.

E10030 is an aptamer targeting PDGF, a key molecule involved in the recruitment and maturation of pericytes. Pericytes in neovascular tissue have been shown to be protective and play a major role in anti-VEGF treatment resistance. E10030 strips the pericytes from the neovascular tissue rendering it highly sens
'/>"/>

SOURCE Ophthotech Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
2. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
3. HIV positive and HIV negative patients have similar survival rates following liver transplant
4. The ALS Association's 'ALS Across America' Focuses On Staying Positive and Involved
5. Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
6. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
7. Economy Got You Down? Use The Principles Of Positive Psychology
8. Standard and Poors Raises Boston Scientifics Rating Outlook to Positive
9. Recent Industry Developments Reaffirm Positive Glucose Industry Outlook
10. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
11. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014 The Cabin Chiang Mai, ... new Alumni Community website – a free ... help them maintain lifelong recovery wherever they live in ... clients the tools to help them maintain their recovery ... part of any reputable treatment programme. As a chronic ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 ... Protocol book review recently updated by Vkool.com, ... of a wide range of simple and ... endometriosis including:,     Increasing ... and dairy products ,     Increasing fiber ...
(Date:7/14/2014)... 2014 Reha Technology today announced ... portable and full-featured upper extremity robotic trainer that ... interactive games and challenges in a lightweight and ... , Armotion combines a variety of ... maximize the therapy effect for patients with severe ...
(Date:7/14/2014)... July 14, 2014 Love Digits LLC ... called Love Digits. The App brings ancient astrology to ... to quantify their compatibility using a five-star rating system. ... people can instantaneously test their compatibility for love and ... , The app’s five-star rating system generates a weighted ...
(Date:7/14/2014)... MT (PRWEB) July 14, 2014 New ... Women's Voices for the Earth examines toxic ... majority of women nationwide, including specific chemicals that may ... as additives and fragrances that may put women’s health ... science and research, Alexandra Scranton , the potential ...
Breaking Medicine News(10 mins):Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 2Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 3Health News:Reha Technology Launches the Armotion™, a Device for the Rehabilitation of the Upper Extremity 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5
... this country has nearly doubled in the past 20 years. ... therapists are charged with the task, but many are falling ... lack scientific rigor. This is in part because many of ... for-profit training centersare not grounded in science. A new ...
... , BOSTON, Oct. 2 Hess Corporation will present two $50,000 ... Foundation and the other to Children,s Hospital Boston,s Trauma Program -- ... Red Sox, home opening day. Aric Morrison, a Hess Retail regional ... , Hess Corporation promised to donate $500 for every home run ...
... award today for excellence in research, advancing oral health ... will receive the 2009 American Dental Association,s (ADA) Gold Medal ... formal presentation during a meeting of the ADA,s House ... once every three years, the award honors individuals who contribute ...
... highest honor on Kenneth L. Kalkwarf, D.D.S. at its 150th ... American Dental Association (ADA) will honor Kenneth L. Kalkwarf, D.D.S., ... Session and World Marketplace Exhibition in Honolulu. The Distinguished Service ... individual. , ADA President John S. Findley, D.D.S., ...
... 2 Beginning October 1st, The Peninsula Chicago will dedicate ... Month and several cancer research and education organizations. , "We ... cancer in some way and this is why we at ... Zec, general manager of The Peninsula Chicago. "In addition to ...
... 2 Pillar Capital is pleased to announce its acquisition ... to an order of the Bankruptcy Court for the District ... free and clear of claims. The Medico Labs business ... in 2000, manufactures and distributes private label and store brand ...
Cached Medicine News:Health News:Where's the science? The sorry state of psychotherapy 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 3Health News:ADA's 2009 Gold Medal Award Presentation Set for 150th Annual Session 2Health News:Dental Educator to Receive the ADA Distinguished Service Award 2Health News:Dental Educator to Receive the ADA Distinguished Service Award 3Health News:The Peninsula Chicago Gives Back During Breast Cancer Awareness Month 2Health News:Pillar Capital Announces Acquisition of Medico Labs' Assets 2
(Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
(Date:7/14/2014)... , July 14, 2014 BioAdaptives, Inc. ... , Chairman has assumed the roles of President and ... of Ferris Holding, Inc., the company that licensed its ... and its financial supporter. "Mr. ... our early transition as a privately held entity to ...
(Date:7/13/2014)... 13, 2014 Auf ... Tokio veranstalteten F&E-Tagung meldete Astellas ... Neuausrichtung seines Forschungsrahmenprogramms. Die Tagung bot Astellas ... fortgeschrittenen klinischen Programme und die Konzernstrategie des ... bestand darin, aktuelle Meldungen zu den Astellas-Initiativen ...
Breaking Medicine Technology:Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3BioAdaptives Prepares for Next Step 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4
... Calif., Nov. 14 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... devices,for the minimally invasive treatment of venous reflux ... using the VNUS,ClosureFAST catheter were presented today at ... VNUS ClosureFAST(TM) catheter is an endovenous,radiofrequency (RF) ablation ...
... Multi-national study compared FORTEO and the currently ... the treatment of Glucocorticoid-Induced Osteoporosis, INDIANAPOLIS, ... The New England Journal of Medicine, showed ... 1-34, teriparatide [rDNA,origin] injection) significantly increased lumbar ...
Cached Medicine Technology:Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium 2Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium 3FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 2FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 3FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 4FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 5FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 6
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... The Blue Line Wrist Control offers a ... wrist support for Carpal Tunnel Syndrome, tendinitis, ... the wrist. Careful design leaves fingers free ... wrist. Lightweight metal stay can be contoured ...
Combination Oppenheimer with Knuckle Bender - to dorsiflex wrist and flex MCP joints; includes two attachments to extend/flex distal finger joints....
Medicine Products: